Last reviewed 2026-04-22 · How we verify

reteplase 10+10 U

Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin.

Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin. Used for Acute myocardial infarction (AMI) for thrombolysis, Acute ischemic stroke.

At a glance

Mechanism of action

Reteplase is a recombinant plasminogen activator that works by binding to fibrin in thrombi and catalyzing the conversion of plasminogen to plasmin. Plasmin then degrades the fibrin matrix of the clot, leading to thrombolysis. The 10+10 U dosing regimen refers to a double-bolus administration protocol (10 units followed by a second 10-unit bolus 30 minutes later) used to optimize clot dissolution.

Approved indications

• Acute myocardial infarction (AMI) for thrombolysis
• Acute ischemic stroke

Common side effects

• Bleeding (major and minor)
• Intracranial hemorrhage
• Reperfusion arrhythmias
• Hypotension
• Allergic reactions

Key clinical trials

• Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization (PHASE4)
• Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• reteplase 10+10 U CI brief — competitive landscape report
• reteplase 10+10 U updates RSS · CI watch RSS
• Sahlgrenska University Hospital portfolio CI